ERBB2 and neoplasm: A phase I trial evaluating PRS-343 in HER2-positive solid tumours demonstrated encouraging evidence of safety and clinical benefit with a correlative pharmacodynamic effect in a heavily pre-treated population, the latter confirmed by CD8+ T cell immunohistochemistry on tumour biopsies pre and post treatment [89].